Skip to main content

Table 3 Multivariate analysis: factors influencing PFS

From: Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)

 

Hazard Ratio

95 % CI

p

Delay before treatment

1,00

0,99–1

0,44

≤2 previous treatment lines

0,69

0,27 – 1,74

0,43

Histology : osteoblastic

0,80

0,37 – 1,73

0,57

Treatment by Sirolimus

2,73

1,05 – 7,1

0,04

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us